2:16 PM
Jul 16, 2018
 |  BC Extra  |  Politics & Policy

Biopharma, PBMs battle over HHS drug pricing blueprint

Trade associations representing drug manufacturers, PBMs, hospitals, insurance companies and pharmacies presented drastically differing diagnoses of, and prescriptions for the U.S. drug market in response to the Trump administration’s request for comments about its drug pricing blueprint. The comment period ends July 16.

None of the comments from trade associations and companies reviewed by BioCentury take any responsibility for creating barriers to access to medicines or suggest that companies the trade associations represent should change their business practices. Each interest group presented economic analyses intended to demonstrate that other groups are taking excessive profits, and each praised elements of the HHS...

Read the full 485 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >